To Evaluate Efficacy, Safety, and Tolerability of KX-826 in Male Subjects With Androgenetic Alopecia

PHASE2CompletedINTERVENTIONAL
Enrollment

123

Participants

Timeline

Start Date

January 31, 2022

Primary Completion Date

February 13, 2023

Study Completion Date

February 13, 2023

Conditions
AlopeciaMale Pattern Hair Loss
Interventions
DRUG

KX- 826 dosed at 2.5mg

2.5mg of the investigational drug to be applied topically to scalp twice daily for 24 weeks

DRUG

KX-826 dosed at 5mg

5mg of the investigational drug to be applied topically to scalp once daily for 24 weeks

DRUG

KX-826 dosed at 5mg

5mg of the investigational drug to be applied topically to scalp twice daily for 24 weeks

DRUG

Matching placebo to KX-826

Placebo applied topically to scalp twice daily or once daily for 24 weeks

Trial Locations (10)

33010

Qway Research LLC, Hialeah

33016

Evoution Clinical Trials, Hialeah Gardens

33157

Innovation Medical Group, LLC, Palmetto Bay

33176

Anchor Medical Research, LLC, Miami

33409

Palm Beach Research Center, West Palm Beach

70808

DelRicht Research, Baton Rouge

78229

Clinical Trials of Texas, LLC, San Antonio

92708

First OC Dermatology, Fountain Valley

01915

ALLCUTIS Research, LLC, Beverly

03801

ALLCUTIS Research, LLC, Portsmouth

All Listed Sponsors
lead

Suzhou Kintor Pharmaceutical Inc,

INDUSTRY